NCT05324735View on ClinicalTrials.gov

Pentoxifylline for Treatment of Resistant Major Depression

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

May 4, 2022

Study Completion Date

June 4, 2022

Conditions
Resistant Major Depression
Interventions
DRUG

Pentoxifylline

All participants will receive pentoxifylline 400 mg (orally ingested) twice a day for 12 weeks.

DRUG

Placebo

All participants will receive placebo (orally ingested) twice a day for 12 weeks.

Trial Locations (1)

44001

Hawler Psychiatric Hospital and Private Clinic, Erbil

All Listed Sponsors
lead

Hawler Medical University

OTHER

NCT05324735 - Pentoxifylline for Treatment of Resistant Major Depression | Biotech Hunter | Biotech Hunter